primary breast tumors; plasma
MCF-7; BT-474
-
proliferation (promotes); other pathway/process (other)
RNA-seq; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RT-qPCR; Clinical Sample Validation; Transfection; MTT; Survival Analysis
Circular, and not linear, CNOT2 levels are predictive for progression-free survival time to aromatase inhibitor (AI) therapy in advanced breast cancer patients; circCNOT2 is detectable in cell-free RNA from plasma.
circCNOT2 is present in primary breast tumors and detectable in plasma cfRNA. Functional knockdown of circCNOT2 reduces viability of MCF-7 and BT-474 breast cancer cells. In ER-positive advanced breast cancer treated with aromatase inhibitors, higher circCNOT2 levels predict shorter progression-free survival, while linear CNOT2 does not.
0.7286
The circular RNome of primary breast cancer.
combined biological and clinical study